Transgene SA 2020 IR
The report highlights Transgene's progress in 2020, particularly the clinical advancement of its individualized immunotherapy TG4050 from the myvac platform and the therapeutic vaccine TG4001. The company also initiated clinical trials for BT-001, its first oncolytic virus from the Invir.IO platform. Financially, Transgene secured visibility until 2022, aided by the partial sale of its Tasly BioPharmaceuticals shares. On the ESG front, the company formalized its sustainability policy, focusing on patient commitment, employee well-being, and reducing its environmental footprint.
Company: Transgene SA
Sector: Professional & technical services
Country: France
Year: 2020
Type: IR
Pages: 244
Back to company
Transgene SA
Universal Registration Document
The report highlights Transgene's progress in 2020, particularly the clinical advancement of its individualized immunotherapy TG4050 from the myvac platform and the therapeutic vaccine TG4001. The company also initiated clinical trials for BT-001, its first oncolytic virus from the Invir.IO platform. Financially, Transgene secured visibility until 2022, aided by the partial sale of its Tasly BioPharmaceuticals shares. On the ESG front, the company formalized its sustainability policy, focusing on patient commitment, employee well-being, and reducing its environmental footprint.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2020
Reporting Period
Jan 1, 2020 - Dec 31, 2020
Fiscal Year
2020
Published
Apr 1, 2021
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Renewable Energy
Water Consumption
Women on Board
Women in Management
Employees